Catalog No.
DHD10804
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
(scFv-kappa-heavy)-(scFv-heavy-kappa)
Clonality
Monoclonal
Target
CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1.74 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P15391 & P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
30mM Histidine, pH 5.8, 10% Sucrose, 0.02% Tween 80.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, CD19, AMG103, BITE MT-103, MEDI-538, MT103, bscCD19xCD3, CAS: 853426-35-4
Clone ID
Blinatumomab
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, PMID: 28249141
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults, PMID: 33085860
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia, PMID: 29358182
A review of blinatumomab, a novel immunotherapy, PMID: 26607163
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy, PMID: 27050240
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy, PMID: 33173373
Recent advances on blinatumomab for acute lymphoblastic leukemia, PMID: 31709129
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia, PMID: 27998223
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL, PMID: 30796026
Blinatumomab for infant acute lymphoblastic leukemia, PMID: 32043146
Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, PMID: 30565020
Blinatumomab-Associated Neurological Adverse Events, PMID: 32902938
Blinatumomab, PMID: 31643524
Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults, PMID: 33153370
Blinatumomab: a historical perspective, PMID: 22940266
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study, PMID: 25524800
Blinatumomab, PMID: 29999804
How we infuse blinatumomab, PMID: 32573958
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia, PMID: 31626339
Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease, PMID: 33256906
Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia, PMID: 30947585
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL, PMID: 32881995
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, PMID: 31002989
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study, PMID: 31433496
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia, PMID: 32094465
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia, PMID: 33098744
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab, PMID: 33141929
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma, PMID: 26755709
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage, PMID: 30307611
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia, PMID: 32619115
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy, PMID: 31738832
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia, PMID: 30831480
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy, PMID: 32103893
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy, PMID: 23678006
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study, PMID: 26884582
Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications, PMID: 27209293
Blinatumomab for the treatment of B-cell lymphoma, PMID: 25739952
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis, PMID: 30985931
Blinatumomab for lymphoblastic leukaemia, PMID: 27990053
Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia, PMID: 28494518
Blinatumomab: first global approval, PMID: 25637301
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies, PMID: 30380973
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia, PMID: 28927784
Blinatumomab: A novel, bispecific, T-cell engaging antibody, PMID: 26683683
Targeting non-Hodgkin lymphoma with blinatumomab, PMID: 28532177
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study, PMID: 28355115
Pediatric blinatumomab preparation: Risk assessment on SmPC for software compliance, PMID: 33106105
Blinatumomab for the treatment of acute lymphoblastic leukemia, PMID: 26383529
Blinatumomab provoked fatal heart failure, PMID: 27816725
Blinatumomab-associated vasculitis, PMID: 28879223
For research use only. Not for human or drug use.
